For the first time ever, the FDA approved a molecular test to help tell women just diagnosed with breast cancer if they will have to fight the disease again.
It is called mamma-print, and uses data from 70 different genes to see how aggressive a tumor is.
A computer program uses this information to predict whether a patient has a low or high risk for a cancer relapse in the next five of 10 years.
Now the test does give some false positives and negatives.
Still, FDA experts say the information mamma-print gives doctors is a lot better than having no information in predicting a patient's future health.
New Test Shows Relapse Possibilities for Breast Cancer Patients